Effect of inspiratory pressure support on exercise performance in patients with chronic obstructive pulmonary disease by Doggett, Anita
Effect of Inspiratory Pressure Support on Exercise Performance in Patients with COPD
Effect of Inspiratory Pressure Support on Exercise Performance in Patients 
with Chronic Obstructive Pulmonary Disease
By
Anita Doggett
A thesis submitted in partial fulfilment of the requirements for the degree of
M.Sc. Exercise Physiology 
Dublin City University
t
Effect of Inspiratory Pressure Support on Exercise Performance in Patients with CORD
Declaration
I, the undersigned, declare that the project material, which I now submit, is my own work, that 
any data presented is accurate and was collected and analyzed by myself. Any assistance 
received by way of borrowing from the work of others has been cited and acknowledged within 
the work. I make this declaration in the knowledge that a breach of the rules pertaining to 
project submission may carry serious consequences. I am aware that the project will not be 
accepted unless this form has been handed in along with the project.
Signed: Date:
Effect of Inspiratory Pressure Support on Exercise Performance in Patients with COPD
Acknow ledgem ents
I would like to thank the following:
Prof. Niall M. Moyna for his valuable assistance in this project, and my academic 
development in general
My husband Niall and children Lauren and Evan for their continuing support.
ABSTRACT
Title: Effect of inspiratory pressure support on exercise performance in patients with chronic 
obstructive pulmonary disease.
Purpose: This study examined the effects of a non-invasive ventilator on submaximal and 
maximal exercise performance in patients with chronic obstructive pulmonary disease 
(COPD).
Methods: Fourteen men (66.0 ± 7.4yr) and six women (59.0 ± 7.4yr) with a diagnosis of 
COPD, a forced expiratory volume! (FEVi) <40%, and the ability to tolerate 12 cmH20 of 
pressure on a non- invasive ventilator performed two maximal exercise tests on a cycle 
ergometer, with and without ventilatory assistance prior to exercise. Blood samples, 
respiratory metabolic measures, heart rate and rating of perceived exertion (RPE) were 
obtained throughout each exercise test.
Results:
Peak work rate (W), total exercise time, and respiratory rate were higher (p<0.05) when 
exercise was preceded by ventilatory support compared to no support. There was no 
difference in peak oxygen uptake (V 02), carbon dioxide (V C 02,), heart rate (HR), minute 
ventilation (VE), tidal volume (VT), blood lactate or RPE between the two experimental 
conditions. A total of 12 subjects completed at least 5 stages of the exercise protocol, and 
their physiological response during exercise with NIV and without NIV were compared. RPE 
was significantly lower during the first 3 min in the NIV condition than the no NIV condition. 
Circulating levels of blood lactate were lower (p<0.01) during stage 3 in the NIV than the than 
no NIV condition. There was no difference in RR, VT, HR, %HR, VE, V 0 2and % V 02 between 
the two experimental conditions during sub maximal exercise.
Conclusions: Application of non-invasive ventilatory support prior to exercise improves
maximal exercise performance, but has no effect on cardio-metabolic response during 
submaximal exercise in patients with COPD.
Effect of Inspiratory Pressure Support on Exercise Performance in Patients with COPD
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CHAPTER 1 
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death 
worldwide, and is predicted to further increase in the coming decades (1). It is a group of 
disorders characterised by progressive limitation in predominantly expiratory airflow that is 
partially reversible by bronchodilator, or anti-inflammatory therapy (2). A post bronchodilator 
(salbutamol) FEV1 < 80% of predicted value in combination with an FEV1/FVC < 70% during 
spirometry, confirms expiratory airflow that is partially reversible by bronchodilator (1).
Treatment modalities in COPD include both invasive and non-invasive procedures. 
Invasive procedures include endotracheal tube, laryngeal mask, and tracheotomy. Non- 
invasive ventilation (NIV) refers to the provision of ventilatory support through the upper 
airway, with the use of a face mask. NIV ventilators increase the volume of air inhaled into the 
lungs. This augments alveolar ventilation (VA), by decreasing blood pH, arterial carbon dioxide 
content (PaC 02) and respiratory rate (RR) in patients with COPD (3). This procedure is 
currently used in patients with COPD who are in acute hypercapnic respiratory failure 
(PaC02>6kPa) (3). A major advantage of NIV is that it delays and/or prevents the need for 
intubation.
Lung function does not appear to limit exercise performance in healthy individuals (4). 
In contrast, physical activity levels, particularly activities of daily living (ADL) are compromised 
in patients with COPD (5). Other co-morbidities such as cardiovascular disease (CVD), 
osteoporosis, mytrophy, and anxiety, may also restrict physical activity in these patients. 
Therapies that are aimed to enhance physical activity levels have the potential to benefit this
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patient group. The aim of the present study is to examine the effect of non-invasive ventilatory 
support on exercise performance in patients with COPD
Rationale:
COPD patients have higher respiratory rates and reduced tidal volumes (VT) at rest 
due to major abnormalities in respiratory mechanics. This inability of the respiratory system to 
maintain adequate alveolar ventilation encroaches on the oxygen available to the non- 
respiratory muscles, which in turn may limit exercise capacity. NIV in the form of inspiratory 
pressure support (IPS) has been shown to augment VA by delivering pressure support during 
inspiration. This is due primarily to an increase in VT and decrease in RR. Improvements in 
pulmonary efficiency due to the provision of IPS prior to exercise may Improve submaximal 
and maximal exercise performance.
Aims of the Study
The primary aim of the present study is to examine the effect of the administration of 
non-invaslve ventilatory support prior to exercise on submaximal and maximal exercise 
performance in patients with COPD. The study will specifically examine the effect of the 
administration of non-invasive ventilatory support prior to exercise on VT, RR, minute 
ventilation (VE,), V 0 2, carbon dioxide (V C 02), blood lactate and rating of perceived exertion 
(RPE).
It is hypothesized that the administration of NIV support prior to exercise will improve 
pulmonary efficiency and augment submaximal and maximal exercise performance in patients 
with COPD. Compared to no ventilatory support, the administration of NIV prior to exercise in 
patients with COPD will result in a lower VT, RR, VE, V 0 2, V C 02, blood lactate and RPE during 
each stage of a maximal exercise test.
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CHAPTER II: 
REVIEW OF LITERATURE
Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the 
upper airway with the use of a facemask. Different types of ventilators have been used to 
provide NIV. These include inspiratory pressure support (IPS), bi-level pressure support 
(BIPAP), and proportional assisted ventilation (PAV). Patients with COPD who are in acute 
hypercapnic respiratory failure are routinely treated with NIV ventilators. This chapter will 
review previous studies that have examined the effect of ventilatory support on exercise 
performance, in patients with COPD.
Structure and Function of the Lungs
The primary purpose of the respiratory system is to provide oxygen (0 2) to the tissues 
and to remove carbon dioxide (C 02). This exchange of gases occurs at two levels termed 
internal and external respiration. Internal respiration refers to the use of oxygen within the 
mitochondria to generate ATP by oxidative phosphorylation and the production of C 0 2 as a 
waste product. External respiration involves the movement of air into and out of the lungs 
(pulmonary ventilation), and the exchange of 0 2 and C 0 2 between the lungs and blood by 
diffusion.
The major organs of the respiratory system are the lungs, which are located in the 
thoracic cavity. Each lung is divided into lobes; the right lung has three lobes and the left lung 
has two lobes. Air moves into and out of the lungs by way of the upper airways, and a 
network of passageways called the respiratory tract. The exchange of 0 2 and C 0 2 occurs in 
small air sacs called alveoli. Millions of small pulmonary capillaries are wrapped around the 
alveoli, to provide an increased surface area for gas exchange.
Effect of Inspiratory Pressure Support on Exercise Performance in Patients with COPD
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The conducting zone of the airways consists of the trachea, bronchi, and the terminal 
bronchioles. The primary function of the conducting airways is to provide a passageway 
through which air can enter and exit the respiratory zone where gas exchange occurs. The 
conducting airways contain approximately 150 ml of air and are considered “dead space” 
because due to the fact that this air does not participate in gas exchange with blood. The 
terminal bronchioles divide into the respiratory bronchioles, which in turn terminate in the 
alveolar ducts. The alveoli ducts lead to the alveoli, where gas exchange occurs. The 
arrangement of the structures in the respiratory zone maximizes surface area and minimizes 
thickness in order to facilitate the diffusion of 0 2 and C 0 2 between the external environment 
and blood.
Chronic Obstructive Pulmonary Disease (COPD)
COPD refers to a group of disorders characterised by progressive limitations in 
predominantly expiratory airflow that is partially reversible by bronchodilator or anti­
inflammatory therapy (2). The term is often used to describe patients with advanced airflow 
limitation. Emphysema, chronic bronchitis, and asthmatic bronchitis are the three disorders 
categorized as COPD.
Emphysema is defined as a permanent, abnormal air-space enlargement that occurs 
distal to the terminal bronchiole, and includes destruction of the alveolar membrane. When 
the emphysema is limited to the respiratory bronchioles, the disease is categorized as 
centrilobular. When the air spaces are involved the disease is categorized as panlobular (7).
Chronic bronchitis is defined as the presence of chronic cough with sputum production 
for at least three months a year, for more than two consecutive years (7). Asthmatic bronchitis 
is a combination of asthma and bronchitis. Asthma is an inflammatory disease of the airways
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that results in reversible airflow limitation (7). The severity of COPD can be classified into four 
stages (Table 1).
Table 1: Classification of COPD
Stage COPD Disease Severity Characteristics
I At risk
Normal spirometry
Chronic symptoms (cough, sputum production)
II Mild
FEV1/FVC <70%
FEV1 >80% predicted, with or without chronic 
Symptoms (cough and sputum)
III Moderate
FEV1/FVC <70%, 30%<FEV1 <80% predicted 
With or without chronic symptoms
IV Severe
FEV1/FVC <70%
FEV1<30% predicted or FEV1<50% + respiratory 
failure or clinical signs of right heart failure
Gold 2001 (1)
Risk Factors for COPD
A number of host and environmental factors have been identified that contribute to 
COPD risk. The primary host factors are categorised as genetic, airway hyper responsiveness 
and lung growth development.
Genetic Factors
The genetic risk factor contributing to COPD risk that is best characterized is a rare 
hereditary deficiency of the serum glycoprotein, alpha-1-antitryspin (AAT) or alpha-1 -protease 
inhibitor. A single gene on chromosome fourteen codes ATT. It is produced and released by 
the liver into the bloodstream, and inhibits the activity of neutrophil elastase and collagenase 
(7). These enzymes are produced by activated neutrophils in the fluid lining the alveolus. 
Elastase and collagenase destroy various components of the extracellular matrix when 
released into the interstitium or alveolus, and cause emphysema (7). Tobacco smoke 
stimulates excess release of these enzymes and subsequent increased lung degradation.
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This hereditary deficiency of the blood component AAT occurs primarily in Caucasians (2), 
and accounts for <1% of patients with COPD (7).
Airway Hyper Responsiveness and Abnormal Lung Growth
Airway hyper responsiveness and lung growth have recently been identified as host 
factors that may influence the development of COPD. Airway hyper responsiveness may 
occur when the lungs are exposed to irritants, dust and sensitising agents, especially in 
airways already damaged by other occupational exposures, such as cigarette smoke (1).
Abnormal lung growth may be related to processes occurring during gestation, and to 
birth weight (8). Abnormal spirometry defined as a postbronchodilator FEV1< 80%) of the 
predicted value in combination with an FEV1/FVC <70% may identify individuals who may be 
at risk of developing COPD (1).
Environmental Factors
Cigarette smokers have a higher prevalence of pulmonary function abnormalities, and 
respiratory symptoms that lead to COPD. However, not all smokers develop COPD, which 
suggests that genetic and environmental factors may interact to modify individual risk (1). 
Passive exposure to cigarette smoke may contribute to respiratory symptoms that lead to 
COPD by increasing lung exposure to inhaled particles and gases (1). COPD may also result 
from prolonged or intense exposure to occupational dusts and chemicals (vapours, irritants, 
fumes). Few studied have examined the harmful effects of high levels of urban air pollution on 
the development of COPD.
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Pathology and Pathophysiology of COPD
COPD is characterised by pathological changes in the central airway and peripheral 
airways, lung parenchyma, and the pulmonary vasculature. The central airways are the site 
for excess mucus production due to the presence of enlarged mucus secreting glands and 
goblet cells (1). The peripheral airways have a smaller diameter size than the central airways.
Destruction of lung parenchyma occurs primarily in patients with COPD (1). It involves 
the dilation and destruction of the bronchioles in the peripheral airways. As the disease 
advances, destruction may spread to the pulmonary capillary bed. AAT deficiency is also 
thought to be a major mechanism in emphysematous lung destruction.
Morphological changes in pulmonary vascular structure are evident in patients with 
COPD. Thickening of the intima is one of the first structural changes that occur in the early 
stages of the disease. This is followed by an increase in smooth muscle proliferation, and 
infiltration of the vessel wall by inflammatory cells (9). Respiratory symptoms such as chronic 
cough and sputum production normally accompany these vascular changes. These 
symptoms may be present for many years before other symptoms or pathological changes 
become evident.
Airflow limitation due to destruction of bronchioles may alter the ability of the small 
airways to adequately transfer inspired air to the gas exchange regions of the lungs. In 
advanced COPD, peripheral airways obstruction, parenchyma destruction and vascular 
abnormalities may reduce the capacity for gas exchange (1), resulting in hypoxemia and 
hypercapnia (1). Patients with COPD may develop pulmonary hypertension, which in turn may 
lead to cardiovascular complications.
13
Effect of inspiratory Pressure Support on Exercise Performance in Patients with COPD
Clinical Evaluation of COPD
A medical history, physical examination and pulmonary function test are commonly 
used to diagnosis COPD.
Medical History
The medical history is used to assess exposure to risk factors and history of asthma, 
allergy, sinusitis, respiratory infections in childhood, and other respiratory diseases. Family 
history and any pattern of symptom development such as cough and sputum production is 
normally documented.
Physical Examination
The physical examination is used to screen for the presence of increased respiratory 
rate, prolonged exhalation, bronchospasm, edema or corpulmonale, and involves an 
assessment of the accessory respiratory muscles and rib cage. Chest x-ray, arterial blood gas 
measurements, and a 1-antitrypsin deficiency screening may also be undertaken during the 
physical examination.
Pulmonary Function Tests
Standard pulmonary function tests including spirometry/bronchodilator response, lung 
volume assessment by nitrogen washout and diffusion are commonly used to assess for 
severity, predict prognosis, and monitor progression of COPD.
Spirometry involves measuring maximal inhalation (forced vital capacity, (FVC)), and 
the volume of air exhaled during the first second of exhalation (FEVi) during a forced 
manoeuvre. Patients with COPD have a decrease in both FEVi and FVC.
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A bronchodilator response test (BDR) involving the administration of salbutamol, 
followed by a repeated spirometry is commonly undertaken to evaluate the presence of airway 
reversibility. An improvement in FEV1>15% of the baseline value is indicative of airway 
reversibility. The presence of a post bronchodilator FEV1 < 80% of the predicted value in 
combination with an FEV1/FVC <70% confirms the presence of airflow limitation that is not 
fully reversible (1). FEV1/FVC <70% is considered an early sign of airflow limitation.
Lung Volumes
Additional diagnostic and functional indices of lung capacity and volume can be 
obtained by assessing functional residual capacity (FRC), total lung capacity (TLC), tidal 
volume (Vt), expiratory reserve volume (ERV) and residual volume (RV) using a nitrogen 
washout procedure. The test involves measuring the patient’s baseline nitrogen level from 
tidal breathing. This is followed by breathing 100% oxygen on a closed system. RV, TLC, and 
FRC are usually increased in COPD (1). A high value for TLC indicates hyperinflation of the 
lungs, and a high RV indicates air trapping in the lower regions of the lung
Single Breath Diffusing Capacity (DLCO):
Ventilation is defined as the exchange of air between the atmosphere and alveoli by 
bulk flow. Diffusion is the exchange of 0 2 and C 0 2 between the alveolar air and blood in the 
lungs. In healthy individuals, ventilation and blood flow distribution are evenly distributed to 
each alveolus. This maintains equilibrium between gases in the alveoli and the blood flow in 
the capillaries. There is a mismatch between alveolar ventilation (VA) and blood flow (Q) in 
patients with COPD.
Ventilation/perfusion (VA/Q) inequality is the term used to describe the mismatch 
between ventilation and blood flow in an alveoli. When VA/Q inequality exists, not all alveoli in
15
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the lung receive the same level of ventilation. Blood flow may also be unevenly distributed 
among the alveoli (10). This may alter the partial pressure gradients, and impair gas 
exchange in the lung. Partial pressure gradients facilitate the diffusion of 0 2 and C 0 2 during 
respiration. An inequality in VA/Q results in a decrease in arterial and venous P 02 and an 
increase in arterial and mixed venous P C 02.
There is an uneven distribution of ventilation and perfusion in patients with 
emphysema due to emphysematous destruction of the terminal lung. The ability to redirect 
perfusion away from poorly ventilated areas is impaired in patients with bronchitis (7), due to 
airway inflammation. Minute ventilation (VE) in these patients becomes limited by airflow 
limitation.
The magnitude of diffusion depends on the surface area of the pulmonary capillary 
bed, and the matching between ventilation and perfusion within the lungs. The diffusing factor 
o f the lung using carbon monoxide gas (DLCO) is a commonly used test to assess the gas 
exchange characteristics of the lung. Carbon monoxide (CO) is a highly soluble gas, which 
combines rapidly with haemoglobin in the capillaries. A 0.3% CO concentration is used during 
the test. The patient is instructed to inhale a maximum breath from FRC, and hold the breath 
for 10 sec to allow the CO gas to transfer across the alveolar beds. At the end of the 10 sec 
the patient exhales maximally and the exhaled breath is analysed to calculate the amount of 
diffusion that has taken place. DLCO decreases in proportion to the severity of emphysema, 
due to the loss of alveolar capillary bed (1). When DLCO is disproportionately low in 
comparison with changes in other pulmonary function tests, emphysema is likely to be the 
cause of the airflow limitation (1).
Some alveoli may not function adequately in gas exchange due to under perfusion of 
blood, or inadequate ventilation relative to alveolar surface area. Physiological dead space
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(VD/VT) is the term used to describe that portion of the alveolar volume with poor regional 
perfusion (or ventilation) of tissues. In patients with COPD, VD/VT may be considered large 
compared to healthy individuals because of the inequality of blood flow and ventilation in the 
lungs (11).
Ventilatory Mechanics During Exercise
In healthy individuals, ventilation increases during exercise due to an increase in tidal 
volume and respiratory rate. Tidal volume plateaus at 50-60% VC, and further increases in 
ventilation are achieved at higher exercise intensities by increasing respiratory rate. Increases 
in VT are achieved by utilising both the ERV and IRV. End-expiratory lung volume (EELV) 
measures the amount of air remaining in the lung after a forced expiration. This volume 
decreases to allow VT to increase.
Individuals with COPD have both inspiratory and expiratory flow limitations. This is 
evident as a reduced maximum expiratory flow rates (MEF) and maximum inspiratory flow 
rates (MIF) during spirometry testing. Airway narrowing causes a reduction in MEF. The 
reduction in MIF results from a combination of inspiratory flow resistance and reduced muscle 
strength (5). Reductions in MEF and MIF will greatly restrict an individual's ability to increase 
ventilation during exercise. Ventilation is limited by the boundaries of the maximal inspiratory 
and expiratory flow volume curves - the highest inspiratory and expiratory flow rates that can 
be generated during exercise (5). Patients with COPD can increase their ventilation during 
exercise by increasing EELV. This will increase MEF and MIF so that inspiratory time 
decreases, and the time available for expiration increases. This will result in an elevated VE 
response during exercise at the same relative workload in COPD compared to healthy 
individuals (5).
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Respiratory Muscles
Patients with COPD have skeletal muscle dysfunction due to low levels of physical 
activity. The respiratory muscles function during inspiration and expiration. In a healthy 
individual, the diaphragm, external intercostals, and the accessory muscles (scalenes and 
sternocleidomastoids) are active during exercise. The internal intercostals and the 
abdominals (rectus transverse, abdominus, abdominal obliques) are active during expiration. 
These respiratory muscles are active contributors to the respiratory movements of breathing, 
both at rest, and during exercise. The abnormal distribution of blood flow within the respiratory 
muscles (5) also impairs muscle perfusion and causes hypoxia in these patients. High/low 
doses of corticosteroids may cause profound myopathic changes, which may also impair 
respiratory muscle function (5).
Cardiovascular Function and Metabolic Acidosis
There is a linear relation between heart rate and oxygen consumption V 0 2 during 
progressive incremental exercise in healthy individuals. In contrast, COPD patients have a 
higher heart rate at a given V 0 2 during exercise compared to a healthy individual 
(12,13,14,15). Heart rate and oxygen pulse (V 02/heart rate) at peak exercise is usually lower 
in COPD than age and gender matched healthy individuals. There is also evidence that mixed 
venous P 0 2 may be higher than normal in some patients with COPD. This indicates impaired 
oxygen uptake by the working muscles, and/or impairment of the normal redistribution of blood 
flow to working muscles during exercise (5).
Metabolic acidosis is a respiratory stimulant and may further increase the ventilatory 
demands of exercise in patients with COPD (24). Acidosis may occur at a relatively low
1 8
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exercise intensity in some patients with severe COPD (13) due to a) low V 0 2max, b) 
cardiovascular dysfunction, and c) lactate production by the respiratory muscles (24).
Non-lnvasive Ventilation (NIV)
NIV refers to the technique of providing ventilatory support without a direct conduct to 
the airways (3). This form of ventilation is now used widely in patients with COPD. Two types 
of NIV ventilators are commonly used to treat patients with COPD. BIPAP ventilators provide 
pressure support on inspiration (IPAP) and during expiration (EPAP) and IPS ventilators 
provide pressure support only on inspiration. A number of studies have evaluated the benefits 
of NIV when administered during or prior to acute respiratory exacerbations. In contrast, few 
studies have evaluated the physiological effect of inspiratory pressure support ventilators 
during exercise in stable COPD patients
Inspiratory pressure and exercise performance
Van’t Hul, et al., (16) evaluated the effect of inspiratory pressure support on exercise 
endurance performance during an acute bout of exercise. Forty-five patients with COPD 
performed three constant-load endurance tests on a cycle ergometer at 75% of maximal 
workload with no IPS, and with IPS5cmH20, and IPS10cmH20. Patients were attached to the 
ventilator via corrugated tubing and a mouthpiece. Spirometry, lung volumes, DLCO and 
mouth pressure assessments (PI,max, PE, max) were performed prior to each exercise test. 
Endurance times were similar in the control and IPS5cmH20 condition (4.2 ± 2.6 versus 4.4 ± 
2.9 min). In contract, endurance times were greater in the IPS10cmH20 condition than the 
IPS5cmH20 and control condition.
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Polkey, et a l., (6) investigated the effects of IPS administration in COPD patients when 
exercising above the lactate threshold. Patients performed two separate treadmill walks, 
separated by an interval of at least 30 min, with and without IPS. The IPS pressure was 
individually titrated to maximise patient comfort. Arterialised blood was drawn from a hand 
vein at baseline and at the end of exercises. Mean time was higher during the IPS assisted 
walk than the IPS unassisted walk. Plasma lactate levels increased significantly above 
baseline during both the assisted and non-assisted walk. Peak lactate was significantly higher 
at the end of the unassisted walk than the assisted walk. It was concluded that the difference 
in peak lactate levels between unassisted and assisted walk could be attributed to a 
decreased workload in the respiratory muscles. It was further hypothesised that IPS during 
exercise may increase the training benefit of pulmonary rehabilitation.
Using a similar study design, Keilty, et al., (17) investigated the effect of IPS, CPAP 
(Continuous Positive Airway Pressure) and supplemental oxygen during sub maximal treadmill 
exercise in eight COPD patients. IPS (12-15cmH20), CPAP (6 cmH20), and oxygen (2.0 l/min) 
where administered during a treadmill test on 3 separate days. Each treadmill test was 
compared to a control walk using a sham circuit (breathing air via an oxygen mask) and with a 
baseline walk in which patients walked freely on the treadmill. Walking distance increased 
62% in the IPS condition compared to the control walk (sham circuit). There was no change in 
walking distance following administration with either CPAP or oxygen. The provision of IPS 
also reduced breathlessness and increased exercise duration during sub maximal treadmill.
Polkey, et al., (18) examined the possibility that IPS could improve inspiratory muscle 
relaxation rate (MRR) during exhaustive treadmill walking in severe COPD. The inspiratory 
MRR was measured from esophageal pressure during a sniff manoeuvre. Six men with 
COPD underwent a treadmill walk, unassisted and assisted with IPS. There was a 41%
Effect of inspiratory Pressure Support on Exercise Performance in Patients with GOPD
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slowing of the inspiratory MRR (p<0.03) following the assisted walk representing a 
considerable unloading of the inspiratory muscles.
Two published studies that have shown a negative effect of NIV on exercise 
performance. Revill, et al., (19) examined the effects of ambulatory oxygen and IPS at 
14cmH20 administered during a endurance shuttle walk test (ESWT). Ten COPD patients 
underwent ESWT under five test conditions: IPS at 14cmH20, sham IPS <8cmH20, baseline 
walk, oxygen at 2.0 l/min, sham oxygen. Ambulatory oxygen supplementation resulted in 
improved performance time in the ESWT. In contrast, IPS administration decreased 
performance time.
Highcock, et al., (20) evaluated the effect of three bilevel pressure support (BiPAP) 
ventilators (BiPAP S/T 30, Nippy 2 and Vpap II ST) during submaximal treadmill exercise. 
Eight patients with COPD walked to exhaustion while using each ventilator, and a mouthpiece 
only condition. The test order was randomly assigned. Patients also performed four 
unencumbered walks (no mouthpiece/ventilator). The total distance covered during the 
unencumbered walks was 259 ± 123m. With the mouthpiece alone this decreased to 211 ± 
96m and decreased to 145 ± 76m when using the ventilators. There was no difference 
between the various ventilators.
Hawkins, et al., (21) examined the effect of PAV (proportional assisted ventilation) on 
VE, heart rate and arterialised venous plasma lactate concentration (La) during exercise in 
COPD patients. Patients underwent a 6 wk supervised outpatient cycle exercise programme. 
Heart rate, VE and blood lactate levels were assessed before and after each test. Ten patients 
received PAV during exercise, and 9 exercised unaided. Exercise capacity at 6 weeks was 
15.2% and 18.4% higher in the group that used ventilatory assistance and unaided group 
respectively. Plasma lactate was reduced by 30% in the assisted group. The study findings
21
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suggest that maximum exercise capacity can be significantly improved in COPD patients when 
PAV is provided.
A similar study by Dolmage, et al., (22) assessed the impact of PAV and CPAP on 
exercise performance. Ten subjects completed five sessions (1) baseline (2) PAV (3) CPAP 5 
cmH20 (4) PAV + CPAP and (5) sham. Dyspnea was measured using the Borg Scale. 
Subjects reached the same level of dyspnea during all experimental conditions. Total exercise 
time was greater during the PAV + CPAP (p<0.05) (12.88(8.74) min) compared to the sham 
session.
Garrod, et al., (23), examined the benefit of BIPAP incorporated into an exercise 
training (ET) program. Forty-five patients underwent a shuttle walk test (SWT) at baseline 
followed by an eight-week training program. Twenty-three patients were instructed to use a 
BIPAP (16cmH20/ 4cmH20) overnight, or for at least 8 h/d throughout the study period 
Twenty-two patients underwent the ET only. In the BIAP+ET exercise time increased group 
from 169(112) to 269(124) min (p=0.001) compared with the ET group: 205(100) to 233(123) 
min (p=0.19); mean difference (95% confidence interval: 72(12.9 to 131) min. BIPAP + ET 
also showed a significant improvement in arterial oxygenation; mean difference: 3.70 mmHg 
(0.37 to 7.27 mmHg). These findings suggest that NIV may be used to augment the effect of 
rehabilitation in severe COPD.
There is accumulating evidence to suggest that exercise performance is enhanced in 
COPD patients following the administration of IPS during exercise. Additional research into 
the potential benefits of IPS administration prior to exercise in patients with COPD, is 
warranted.
22
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CHAPTER III 
METHODOLOGY 
Patients
Patients [(14 men (66.0 ± 7.7 yr) and 6 women (59.0 ± 7.4 yr)] with a diagnosis of 
chronic obstructive pulmonary disease (COPD) were recruited. Inclusion criteria included a 
forced expiratory volume! (FEVO <40%, and the ability to tolerate 12 cmH20 of pressure on a 
non-invasive ventilator (Nippy 1, Respironics). Patients were excluded if they had an 
exacerbation within the past month, and had been treated previously with non- invasive 
ventilation (NIV). Written consent was obtained in accordance with St. James’s Hospital 
Ethics Review Board.
Experimental Design
Patients visited the Respiratory Laboratory at St. James’s hospital on 3 separate 
occasions. The first visit was used to screen potential patients. A graded maximal exercise 
test with and without the use of the ventilator prior to exercise was performed during the 
second and third visit. Patients did not exercise for 24 h before testing, and fasted for 1 h 
before each testing session. The testing sessions were separated by 48 h. On arrival to the 
laboratory, a 21G indwelling catheter was inserted into a prominent forearm vein to facilitate 
the collection of blood samples. Spirometry was performed followed by a resting period of 10 
min. The patients then undertook a maximal exercise test on a cycle ergometer. Respiratory 
metabolic measures, heart rate, blood samples and RPE were obtained throughout each 
exercise test.
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Experimental Procedures: 
Athroprometrics
Height and weight were measured using a stadiometer (Seca 797, USA). Footwear 
was removed prior to the measurement. Height was measured to the nearest cm, and weight 
was measured to the nearest 0.1 kg.
Spirometry
Spirometry was performed using a metabolic cart (Sensormedics Vmax. 229, Loma 
Linda, CA, USA). The Vmax 229 consists of an analyser module, pneumatics module, 
peripheral device input/output, and operating software. Each manoeuvre consisted of a 
maximal inhalation to total lung capacity (TLC) followed by a quick exhalation that was 
maintained for as long as possible. Patients then re-inhaled to TLC and finally returned to 
normal tidal breathing. Patients were instructed to keep a tight seal around the mouthpiece 
during the manoeuvre. The same investigator offered verbal encouragement during each test. 
Three successful manoeuvres were recorded.
Ventilatory Support Tolerance Test
A tolerance test was performed to insure that subjects were comfortable wearing the 
facemask (Comfort Full, Respironlcs), and that they were able to tolerate an inspiratory 
pressure of 12 cmH20. The pressure on the ventilator was slowly ramped to 12 cmH20.
Ventilatory Support
A facemask was positioned comfortably on each patient, and the ventilator was set at 12 
cmH20 of inspiratory pressure support (IPS). Patients were encouraged to relax and breathe
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normally through the mask. They remained seated for 2 h while wearing the ventilator. Blood 
samples were taken before and after IPS.
Exercise Test
The exercise tests were performed on an electrically braked cycle ergometer 
(Sensormedics er900, USA). Work rate was independent of the pedalling rate. A peripheral 
device interfaced the work rate of the cycle ergometer with the Vmax 229 system at a sampled 
rate of 125 Hz.
Following a 2 min warm-up at zero Watts the work rate was increased 5 W m in '1 for 
women and 10 W m in 1 for men, using a ramp protocol. The controlled ramp signal was 
delivered to the ergometer via a computer (Dell Pentium II processor, Dell Computer 
Corporation, Texas, USA). Patients were encouraged to give their best effort throughout the 
test by the same investigator.
Mass Flow Sensor Heated wire Anemometer- Mode of operation
A mass flow sensor (Sensormedics, Loma Linda, CA, USA) was used to collect 
breath-by-breath measurements of ventilation. The mass flow sensor is a low resistance tube 
with a tapered internal diameter extending from both ends of a laminar flow throat. A cold and 
hot stainless steel wire electrically heated to -180° C and -240° C respectively, are centred in 
the flow stream. These wires are elements in a servo-controller bridge circuit that maintains 
the resistance ratio of the two wires at a constant value. If only the temperature of the inspired 
gases change, then both wires lose heat at the same rate, and no current change is required 
to keep the bridge balanced. As air flows across the wires, the hot wire loses heat more 
rapidly than the cold wire and current is added to keep the bridges balanced at a 3:4 ratio. 
The amount of current required is proportional to the mass flow of the gas. This method 
ensures that the sensor measures only the heat loss from the molecular convection of the
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moving gas stream, and not the artefact due to cooling of the gas as it passes through a 
breathing assembly. The mass flow meter responds to instantaneous flow rates between 0-16 
Lsec'1 and integrated flow between 0-350 L m in'1 with flow resistance <1.5 cmH20/litre/sec. 
The mass flow sensor was outputted to the analyser module of the Vmax 229 and sampled at 
a rate of 125 Hz.
Calibration
A 3-litre volume syringe (Sensormedics, Loma Linda, CA, USA) was used to calibrate 
the mass flow sensor prior to each test. The syringe was connected to the mass flow sensor, 
and stroked 4 times in order to measure inspired and expired volumes. The volumes were 
calculated by expressing 3 litres as a fraction of each measured inspired and expired volume 
achieved during calibration. An average correction factor was calculated for inspired and 
expired volumes, and used to fine-tune the volume measurement. A verification procedure 
was performed. This involved stroking the 3-litre volume syringe four times. Inspired and 
expired volumes were measured using the newly calculated correction factors. In order to 
pass the calibration procedure one of the four strokes had to have an average flow rate <0.5 
I sec'1, and at least one of the four strokes had to have an average flow >3.0 I sec"1.
Blood Pressure
Blood pressure was assessed automatically using a Sensormedics er900 blood 
pressure cuff (Sensormedics Corp., Yorba Linda C, USA).
Pulse Oximetry
A finger oximeter probe (Sat-Trak Pulse, USA) was placed on the middle index finger 
to monitor Sa0 2. The pulse oximeter transmits light through body tissue at two or more
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wavelengths. The intensities of the emerging light is measured and converted into an 
electronic signal for processing.
Respiratory Metabolic Measures
Respiratory metabolic responses were determined using standard open-circuit 
spirometry techniques. Prior to testing, the gas analysers were calibrated with standard gases 
of known concentration.
Gas Analysers
A Vmax 229 Metabolic cart (Sensormedics, Loma Linda, CA, USA) was used to 
assess the respiratory metabolic responses during the exercise test. The Vmax 229 utilizes a 
rapid response non-dispersive infrared measurement technique. An 0 2 and C 0 2 analyser is 
integrated within the Vmax 229.
A small sample of inspired air is drawn through a sample cell, and exposed to an 
infrared light through an optical that is passed through a band-pass filter and the sample cell. 
An infrared detector responds to the amount of infrared light that passes through the sample 
cell. Carbon dioxide absorbs infrared light over wavelengths ranging from 0.7^m to 15.0 ^m. 
The amount of light passing through the sample cell varies according to the concentration of 
C 0 2 in the sample cell. Based on measured levels of infrared light intensity, the analyser 
computes the P C 02 in the gas sample. The C 0 2 analyser is linearly scaled across the 0-100% 
range with a resolution of 0.01 % C 02, and a response time of <130ms (10-90%) at 500 ml min'
1 flow.
The 0 2 analyser is based on the high paramagnetic susceptibility of 0 2. A 
diamagnetic glass dumbbell suspended in a magnetic field rotates in proportion to the P 0 2.
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The analyser is linearly scaled across the 0-100 % range with a resolution of 0.01% 02and a 
response time of <130 m sec'1 (10-90%) at 500 m lm in '1 flow.
Calibration of Gas Analysers
The gas analysers were calibrated using gases of known concentration (BOC gases, 
Dublin, Ireland). The gas composition in tank 1 was 26.00 + 0.02 % 02 and the balance N2. 
The gas composition in tank 2 was 4.00 + 0.02 % C 02, 16.00 ± 0.02 % 0 2 and the balance N2. 
A small bore drying tube connected to the C 0 2 and 0 2 analysers samples the calibration 
gases and inhaled/exhaled air by the subjects. The absorption and evaporative properties of 
the drying tube ensured that the relative humidity in the inhaled/exhaled gas and the 
calibration gas was equilibrated to ambient conditions before being sampled by the analysers. 
Samples of the calibration gas and the gas inhaled by subjects were taken at a rate of 125 Hz, 
The response time of the C 0 2 analyser was synchronised with that of the 0 2 analyser.
Heart rate Monitoring
Heart rate was measured continuously during each test using a 3 lead 
electrocardiogram (ECG) module. A peripheral device input interfaced the ECG module 
between the ECG and the Vmax 229. An ECG signal was displayed on the desktop computer 
(Dell Pentium II processor, Dell Computer Corporation, Texas, USA) throughout the exercise. 
The computer calibrated the heart rate signal using a set signal of one volt (250 beatsm in'1) 
generated by the heart rate monitor and was sampled at a rate of 125 Hz. The ECG signal 
was set at a high pass filter of 20 Hz and a line filter of 50 Hz.
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NIPPY 1 (Respironics) Ventilator
The Nippy 1 (B &  D Electromedical, Respironics) is a pressure controlled, intermittent 
positive ventilator. Ambient air is drawn through a dust filter and compressed by a centrifugal 
fan. An electronically controlled valve controls output airflow. Air is delivered to the patient 
through a close fitting full facemask. The output pressure, timing and alarms are adjusted by 
controls on the panel. As the airflow is servo controlled, the ventilator is able to compensate 
for leaks around the mask. If leaks become too great, the pressure will fall below the pre-set 
low-pressure alarm level.
Air is delivered to the mask during inspiration. This may be triggered by the subject’s 
own inspiratory effort or by the ventilator expiratory timer if there was insufficient inspiratory 
effort. The inspiratory pressure was adjusted with the set pressure control. The inspiratory 
time was set by the inspiratory time control. At the end of the inspiratory time, the exhalation 
valve opened. The subject exhaled through the exhalation valve. If the ventilator did not 
detect an inspiratory effort, the next breath was initiated by the end of the expiratory time, as 
set by the expiratory time control. The trigger was activated when the inspiratory pressure in 
the mask dropped below the level set by the trigger control.
Blood Lactate Analyser
Whole blood lactate levels were determined using a YSI 2300 STAT PLUS analyser 
and expressed in mmol L"1. The 2300 STAT PLUS was calibrated prior to each run. Blood 
samples were analysed in duplicate. Each test tube was positioned in the analyser holder to 
prepare for sampling. A sipper pump piston moved to the sample test tube and travelled 3 
mm below the surface of the fluid. A sipper pump piston retracted and aspirated 25 pL 
sample. The sipper then moved back to a sample chamber, extended and the sample was 
dispended. Values were displayed and printed.
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Statistical Analysis
A paired sample student’s t-test was uses to compare peak data between the two 
experimental conditions. A total of 12 patients completed 6 min o f the maximal exercise test. 
A  two way (condition x  time) repeated measures ANOVA was used to compare differences 
between the two experimental conditions for the first 6 min of the test. Significant main and 
interaction effects were analyzed using paired t-tests with Bonferroni adjustment for multiple 
comparisons. The significance was set at an a-level o f p<0.05. Data are presented as mean 
± standard deviation.
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RESULTS
Patient demographic and clinical characteristics are presented in table 2 and 3 
respectively. Peak workrate, total exercise time and respiratory rate were higher (p<0.05) 
when exercise was preceded by ventilatory support compared to no support (Table 4). There 
was no difference in peak V 0 2, V C 0 2, heart rate, minute ventilation, tidal volume, RPE or 
blood lactate between the two experimental conditions.
Since the total number of completed stages ranged from 3 to 11 it was not possible to 
compare the submaximal physiological responses each min in all subjects. A total of 12 
subjects completed at least 5 stages of the exercise protocol. A repeated measures ANOVA 
was used to compare differences in physiological responses between the two experimental 
conditions in these 12 subjects. There was no difference in demographic data or peak 
exercise data between the 12 patients who completed 5 stages of the maximal exercise test 
and the other 8 patients (x completed less than five and y completed y 5 stages) (Table 5 and 
Table 6). RPE was significantly lower in during the first 3 min in the NIV condition than the 
placebo (Table 7). Circulating levels of blood lactate were lower (p<0.01) during stage 3 in the 
NIV than the placebo group (Table 7). There was no difference in RR, VT, HR, %HR, VE, V 0 2 
and % V 02 between the two experimental conditions during sub maximal performance (Table
Effect of inspirator'/ Pressure Support on Exercise Performance in Patients with COPD
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Table 2: Patient demographics
Variable Mean ± SD
Age (y) 63.4 ± 8.2
Weight (kg) 62.3 ± 12.3
Height (cm) 164.6 ±8 .0
BMI (kg m2) 23.0 ±4.1
Systolic blood pressure (mmHg) 84.5 ± 12.3
Diastolic blood pressure (mmHg) 136.1 ± 17.1
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Table 3: Patient clinical characteristics
Variable N (%)
Patient Historv
Cardiopulmonary disease 0
Pulmonary disease 20(100)
Metabolic disease 0
Cancer 1(5)
Bleeding problems 1(5)
Orthopedic problems 0
Vegetarian 1(5)
Familv Historv n (%)
Hyptertension 4(20)
Diabetes mellitus 5(25)
Cerebrovascular accident* 0
Total cholesterolt 2(10)
BMI > 30 kgm '2 1(5)
Cancer 8(40)
Asthma 20(100)
Angina 2(10)
Prior Ml 1(5)
Prior CABG 0
Alleraies
Food 1(5)
Medication 2(10)
Smokina status
Former (past history of smoking) 20(100)
Current (present smoker) 11(55)
Current alcohol use 11(55)
Medications
Atrovent 2(10)
Seretide 8(40)
Serevent 3(15)
Combivent 11(55)
Beclazone 2(10)
Salbutamol 6(30)
Pulmicort 3(15)
Becotide 6(30)
Intel 1(5)
Oxivent 2(10)
Duovent 1(5)
Steroids 2(10)
Bricanyl 1(5)
‘ Cerebrovascular accident (CVA): encompass problems such as stroke (damage to a group of nerve 
cells in the brain) and cerebral haemorrhage (sudden and abrupt bleed into the tissue of the brain), 
t  Total cholesterol > 5.2 mg/l
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Table 4: Hemodynamic and metabolic variables at peak exercise
Variable
Experimental Condition
NIV No NIV P Value
Workrate (W) 50.20 ± 18.58 44.30 ± 20.90 0.04
V 0 2(rmin'') 0.60 ±0 .23 0.59 10± 0.25 0.74
V C 0 2(lm in'') 0.56 ± 0.22 0.56 ± 0.25 0.86
HRM 121.45 ±20.60 115.90 ± 13.10 0.21
VE(lmin"') 23.43 ± 7.72 22.57 ± 6.92 0.33
RR (breaths m in'1) 31.40 ±6 .10 29.30 ±5 .14 0.03
VT(lmin"') 0.92 ± 0.26 0.95 ± 0.28 0.41
La (m m o lf1) 1.50 ±0 .58 1.45 ±0 .60 0.74
RPE 19.55 ± 1.23 18.85 ± 1.87 0.09
Total time (sec) 308.70 ± 114.90 258.10 ± 124.50 0.02
Values are mean ± SD
Table 5: Demographic and physiological characteristics of patients who completed 5 stages 
and those who completed >5 or > 6 stages of the exercise protocol
Experimental Condition
Variable >5 and >6 stages 
(n=8)
5 stages 
(n=12)
P Value
Age (y) 62.8 ± 7 .7 63.7 ±8 .8 0.04
Weight (kg) 66.7 ± 14.4 59.3 ± 10.1 0.74
Height (cm) 162.5 ±7 .3 166.0 ± 8 .4 0.86
BMI (kg m2) 25.01 ± 4 .2 21.5 ±3 .4 0.21
Diastolic blood pressure (mmHg) 147.0 ± 17.3 132.0 ± 15.0 0.33
Systolic blood pressure (mmHg) 91.2 ± 12.4 79.1± 11.9 0.03
Values are mean ± SD
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Table 6: Peak exercise values for patients who completed 5 stages and those who completed >5 or > 6 stages o f the 
_________ exercise protocol________________________________________________________________________________
Experimental Condition
Variable > 5 and ä6 stages 
(n=8)
5 stages 
(n=12)
P value
Workrate (W)
41.87 ±30.8 45.92 ± 12.06 0.73
V 0 2 (I min'1)
0.58 ± 0.35 0.59 ±0.17 0.90
V C 02 (Im in '1)
0.53 ± 0.34 0.57 ±0.17 0.80
Heart rate (bpm)
122.2 ± 14.0 111.7 ± 11.11 0.08
VE (Im in '1)
21.35 ±8.57 23.3 ± 5.8 0.53
RR (breathsmin'1)
29.12 ±2.41 29.42 ± 6.4 0.90
VT (Im in'1)
0.88 ± 0.32 0.98 ± 0.24 0.43
La (m m o lf1)
1.33 ±0.85 1.52 ±0.38 0.50
RPE
18.25 ±2.25 19.25 ± 1.54 0.25
Total time (sec)
254.5 ± 191.5 260.5 ±58.4 0.93
Values are mean ± SD
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Table 7: Physiological responses at 1 min intervals in patients who completed the first 5 stages of the exercise protocol
Time
Condition 1 min 2 min 3 min 4 min 5 min
Respiratory rate (breathsm in'1)
N oN IV 24.1 ±6 .0 25.3 ± 6.5 24.6 ±4.1 26.4 ± 3.9 28.3 ± 4 .9
NIV 23.5 ±6 .0 24.7 ± 5.5 25.8 ± 7 .5 26.6 ± 8.6 29.9 ± 9.4
Tidal volume (1 min"1)
No NIV 0.71±0.1 0.75±0.17 0.82±0.15 0.87±0.15 0.90±0.20
NIV 0.68±0.2 0.70±0.14 0.76±0.18 0.82±0.18 0.85±0.26
Heart rate (beats min'1)
No NIV 87.30±12.0 89.10±14.8 93.4±11.0 99.8±12.4 104.0±13.0
NIV 90.50± 18.1 87.80±13.9 93.0±17.0 100.0±25.3 105.0±20.4
%HR
No NIV 78.10±6.40 79.68±9.98 83.65±6.14 89.31±7.1 92.96±6.94
NIV 76.10±10.4 74.62±11.7 80.59±17.4 85.07±16.6 88.75±12.5
Minute ventilation (Im in '1)
No NIV 13.53±2.6 14.76±2.9 16.04±2.5 18.54±3.50 20.27±3.60
NIV 12.71 ±3.44 13.80±3.47 15.45±3.59 17.41 ±4.18 19.71±4.56
RPE
NoN IV 8.42±1.16* 8.58±1.10* 10.58±1.08* 12.05±1.6 16.08±2.91
NIV 6.83±0.94* 7.58±1.1* 9.58±1.24* 12.10±1.8 15.0±2.34
Lactate (mmolT1)
NoN IV 1.27±0.42 1.11±0.30 1.05±0.19 1.22±0.31 1.34±0.36
NIV 1.48±0.66 0.80±0.22+ 0.91±0.32 0.94±0.35 1.05±0.36
V 0 2(lm in'')
No NIV 0.26±0.07 0.30±0.06 0.35±0.07 0.43±0.08 0.49±0.11
NIV 0.24±0.08 0.28±0.06 0.32±0.07 0.39±0.08 0.47±0.15
% v o 2
No NIV 44.86±12.4 51.50±10.9 60.28±11.1 74.38±13.1 84.48±15.8
NIV 40.28±9.75 49.22±10.2 56.47±15.7 69.43±18.8 79.41±16.9
Values are MeantSD n=12; * p< 0.05 vs Nippy, fp<0.01 vs Nippy, t  p<0.001 vs Nippy.
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Chapter V: 
Discussion
NIV is an established treatment modality in the management of acute respiratory 
failure in patients with COPD (3). The application of NIV during exercise has been found to 
improve exertional dyspnoea and endurance performance (26). To my knowledge, this is the 
first study to examine the effects of administering ventilatory support prior to exercise in 
patients with COPD. The major findings of the present study is that the application of 
inspiratory pressure support (IPS) prior to exercise increased exercise duration, RR and 
maximal workload in patients with COPD. There was no effect of pre-exercise ventilatory 
support on V 0 2, % V 02, V C 0 2, HR, %HR, VE, and RPE during submaximal and maximal 
exercise. The % V02 and %HR corresponding to the VT and LT were similar in both 
experimental conditions.
Intrinsic positive end expiratory pressure (PEEP) reflects the recoil pressure of over 
inflated lung (3), and contributes to a positive intrathoracic pressure at end expiration. At rest, 
the inspiratory muscles need to generate an inspiratory pressure to overcome PEEP before 
airflow can begin. PEEP is increased at rest and during exercise in COPD patients (17). This 
may limit exercise performance in these patients.
We did not assess if IPS unloaded the inspiratory muscles prior to exercise. However, 
a study by Polkey, et al., (18) reported that the maximum relaxation rate (MRR) of the 
inspiratory muscles was slowed following the administration of IPS. Six men with severe 
COPD performed two treadmill walks separated by 30 min, to an intolerable dyspnea; with and 
without IPS. IPS was adjusted to optimize patient comfort. A Sniff (Sn Pes MRR) manoeuvre 
involving a deep inhalation through the nostril was performed over a 10 min following each
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walk. During the sniff manoeuvre, esophageal and gastric pressures (Pes and Pgas) were 
recorded with a balloon catheter. Transdiaphragmatic pressure (Pdi) was obtained as the 
difference between Pes from Pgas. Pes MRR was calculated as the maximal rate of decay of 
pressure divided by peak pressure over 50 ms, and was reported as % pressure loss/10 ms. 
Sn Pes MRR had slowed by 41% when exercise was performed without with no IPS compared 
to 20% with IPS. This represents a considerable unloading of the inspiratory muscles.
IPS may improve exercise performance by allowing patients to adopt a more effective 
breathing pattern, by lowering RR and increasing VT. Previous studies have reported 
increases in VT and decreases in RR during exercise with IPS, due to improved alveolar 
ventilation (25, 27). In the present study, peak RR was 7% higher during exercise with IPS 
compared to no IPS. There was no difference in submaximal or peak VT between the two 
experimental conditions. This is consistent with breathing patterns observed in patients with 
COPD when exercising without any NIV. The higher RR may be due to the fact that these 
patients were exercising at higher workloads when IPS was given prior to exercise compared 
to no IPS.
At low exercise intensities oxygen supply equals the oxygen demand. As the exercise 
intensity increases, the oxygen delivery system may be unable to keep up with the demand 
resulting in a greater reliance on anaerobic glycolysis, and accumulation of lactic acid. The 
resultant dissociation of H+ from lactic acid will result in a decrease in intracellular pH. High 
Low pH levels will have a deleterious effect on muscle function, and limit exercise 
performance. In some COPD patients, decreased oxygen delivery due to increased 
pulmonary vascular resistance, arterial hypoxemia, and abnormalities in the skeletal muscles 
may also limiting aerobic energy production resulting in early onset of lactic acidosis (31).
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The exercise intensity at which lactate production begins to exceed the rate of 
removal is termed the lactate threshold (LT). Most ADL are performed at intensities at or 
below the LT. Polkey, et al., (6) suggest that the physiological benefit resulting from 
participation in pulmonary rehabilitation is more likely if exercise is performed above LT. In the 
present study we were unable to detect the LT in any of our COPD patients. The inability to 
detect the LT may be due to the fact that these patients having difficulty in achieving adequate 
levels of ventilation needed to eliminate the additional C 0 2 generated during exercise. In 
addition, severe deconditioning related to inactivity (28), malnutrition, low anabolic hormone 
levels and myopathy related to corticosteroid use (31), may also limit exercise performance in 
patients with COPD. This is in contrast to others (29, 30), who found that the LT occurred at a 
low relative workload in a small number of patients with COPD.
There was no difference in submaximal or peak blood lactate between the two 
experimental conditions. To my knowledge, this is the first study to investigate peak blood 
lactate following the administration of ventilatory support prior to exercise in patients with 
COPD.
Polkey et al., (6) found that the administration of IPS had an effect on exercise 
duration during treadmill walking to severe dyspnoea in 8 men (70 ± 8 yr) with severe COPD. 
Limited information was provided with regard to the exercise protocol and treatment modality 
used in this study. IPS was set individually and was administered during one of the treadmill 
walks. Walking time was increased by 5.5 min and 13.6 min in the control and IPS condition 
respectively. The recovery time of 30 min between two maximal exercise tests may have 
been too short for elderly patients with severe COPD.
The VT is commonly used as a non-invasive method to determine LT. We were 
unable to detect VT in any patient using the ventilatory equivalent or V-slope method. It is
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possible that the patients were unable to exercise sufficiently to reach VT possibility due to 
decreased ventilatory capacity and increased ventilation requirement. Decreased ventilatory 
capacity is due to airflow limitation combined with increased airway resistance (31). Increased 
ventilatory requirement is primarily due to inefficient ventilation of the lungs consequent to the 
mismatching of ventilation- perfusion (certain regions of the lungs are hypoventilated, whereas 
other are hyperventilated) (31). These factors contribute to reduced exercise tolerance and 
make detection of VT difficult in patients with COPD. Irregular breathing patterns may have 
also contributed to the difficulty of determining VT in the present study. The detection of VT 
may not be possible in many patients with COPD who fail to show a disproportionate increase 
in VE in response to metabolic acidosis.
Although the increments in workload were relatively small (5 W  women, and 10 W 
men), the exercise protocol may still have been too aggressive to detect VT. A  less aggressive 
protocol may facilitate the detection of VT. Debigare, et al., (32), examined the effect of work 
rate on exercise responses in patients with COPD. Nine men and one woman (65 ± 5 yr) with 
severe COPD underwent three ergometer exercise tests. Exercise testing was conducted 
over three consecutive days and the testing was randomized. Work rate was increased every 
min by 5 W.min "1, 10 W.min or 20 W.min '1 increments. Peak workrate was 65% higher 
when the work rate increment was increased from from 5 W.min ‘1 to W.min In contract, 
peak values for V 0 2, VE, and HR were independent of the exercise protocol. These findings 
show that for a given work rate, V 0 2, VE, and HR were lower with higher work rate increments 
(20 W.min -1) during exercise in patients with COPD. It was suggested that peak V 0 2 rather 
than Wpeak should be used to quantify exercise tolerance in patients with COPD (32). 
Patients with COPD have slower V 0 2, VE, and HR responses during ergometer testing 
compared to healthy individuals (33).
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In the present study, the administration of IPS prior to exercise had no effect on V 0 2 
and V C 02 at peak exercise or during submaximal exercise. This finding suggests that IPS 
may not have unloaded the inspiratory muscles prior to exercise. However, a previous study 
(16) reported that V 0 2 and V C 02 were significantly reduced during an acute bout of exercise. 
Forty-five patients with COPD performed three constant-load endurance tests on a cycle 
ergometer at 75% of maximal workload with no IPS, and with IPS5cmH20, and IPS10cmH20. 
Endurance times were greater in the IPS10cmH20 condition than the IPS5cmH20 and control 
condition. A reduction in V 0 2  (5%) and VC 02 (4%) was found at the iso-time (peak exercise 
time with IPS5cmH20) with IPS10cmH20. This suggests that the inspiratory muscles were 
unloaded during exercise with IPS.
Perceived exertion is defined as perception of effort, stress or discomfort during 
exercise (34). Central (respiratory-metabolic) and peripheral /non- specific factors regulate 
perception of effort (34). Respiratory-metabolic mediators such as VE, V 0 2, V C 0 2, HR and 
blood pressure influence ventilatory drive during exercise (34). Peripheral physiological 
mediators are localized to the limbs, trunk, and upper trunk (34). The physiological processes 
that are thought to mediate the intensity of peripheral exertional perceptions are; metabolic 
acidosis, fast-s low  contractile properties of skeletal muscle fibres, muscle blood flow and 
blood borne energy substrates (34). Non-specific mediators such as hormonal, temperature 
regulations and pain reactivity are not directly linked to peripheral or respiratory metabolic 
signals, but do continue to effort sensations during exercise.
RPE is used for both the prescription and regulation of exercise in spot, clinical and 
recreational applications. In the present study, there was no difference in RPE between the 
two experimental conditions. It had been hypothesised IPS would improve pulmonary
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efficiency by adopting a more efficient breathing pattern, therefore, decrease the stress or 
discomfort that is felt during exercise.
In the present study, we were unable to assess submaximal exercise, due to the 
nature ramp protocol used. The large interindividual variations in fitness levels also made it 
difficult to compare the physiological responses at relative workloads. Future studies should 
exercise patients at the same relative workloads. This workload should be compatible with the 
intensities associated with the ADL. This would be particularly beneficial to patients with 
COPD, as they perform ADL at submaximal intensities.
The ventilator used in the present study could only provide pressure support on 
inspiration, with only one intensity level selected. There is a large selection of NIV ventilators 
on the market with improved technical performances that provide pressure support both on 
inspiration and expiration (BiPAP) that may show greater improvements compared to the 
ventilator used in the study. Future studies should focus on comparing different intensity 
levels of NIV support, and possible examine the benefits of wearing the ventilator for longer 
period of time prior to exercise. In particular, research should examine P sniff MRR during 
exercise when IPS has been administered prior to exercise.
IPS has been shown to be a safe and effective aid if administered during exercise in 
patients with COPD (6, 17,18). The present findings indicate that IPS administered prior to 
exercise will enhance exercise performance by increasing exercise duration and maximal 
workload. It has been suggested that IPS used during exercise may increase the benefit of 
pulmonary rehabilitation (6). This hypothesis warrants further experimental research to 
evaluate not only any ergogenic properties of IPS but also any ventilation improvements in 
patients with COPD.
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Chapter VI:
Conclusions and Recommendations 
Conclusions
The findings of this investigation warrant the following conclusions:
1) Work rate, RR, exercise stage and duration was greater with ventilatory support prior 
to exercise. This is the first study to show these findings.
2) IPS was not effective in reaching AT or LT when administered prior to exercise. V 0 2, 
VE, VT, V C 0 2 were not significantly higher with ventilatory support prior to exercise.
Recommendations
Based on the present experimental findings, the following suggestions are proposed for future
research regarding the ergogenic effect and health benefits of IPS:
1) Future studies should exercise patients at the same relative workloads. The 
workloads should be compatible with the intensities associated with the ADL.
2) Future investigations should compare different intensity levels of NIV support, and 
possible examine the benefits of wearing the ventilator for longer period of time prior 
to exercise.
3) Determine the effects of other modes of NIV (BiPAP, PAV) in patients with COPD 
when administered prior to exercise.
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Appendices
Subject Informed Consent Form 
St. James’s Hospital
Title of Project:
Effects of inspiratory pressure support on exercise performance in patients with chronic 
obstructive pulmonary disease
Principal Investigator: Ms. Anita Doggett, Snr. Respiratory Technician, St. James’s Hospital. 
Other Investigators: Prof. Niall Moyna, Dublin City University.
Study Physician: Dr. Finbarr O’ Connell, Respiratory Consultant, St. James’s Hospital. 
Introduction:
Chronic Obstructive Pulmonary Disease (COPD) is a common disease of the lung. It is a 
progressive Illness affecting people in different ways. Depending on the severity of the 
disease, it can limit your daily activity. Exercise intolerance is the most common consequence 
of this disease. Therefore, regular exercise activity is one of the main approaches suggested 
in the treatment of this illness. It has a beneficial effect on improving your fitness level.
This study will examine the benefits of a breathing ventilator given prior to exercising on a 
bicycle. This research study will take place at St. James’s Hospital Respiratory Laboratory 
and will last approximately three days.
Procedure:
This is what will happen during the research study 
Study day 1 (pre screening day)
This visit to the Respiratory Laboratory will last approximately two hours. On arrival I will have 
my weight and height measured for a breathing test.
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I will then complete the short breathing test called a Spirometry. This involves a blowing 
manoeuvre into a plastic mouthpiece attached to a computer. This test measures the amount 
o f air I can take in on inspiration and blow out on expiration.
The level of oxygen in my blood (%Sao2) will be measured using a finger probe (Novametrlc 
oximeter). Following this, I will complete a "pressure tolerance test” using the ventilator. This 
device will make it easier for me to breathe.
Study day 2:
On the morning o f study day two, I will undergo a repeated breathing test. I will then complete 
an exercise stress test to determine my fitness level. A polyethylene cannula/line will be 
inserted into my vein in my forearm to allow blood samples to be taken. A blood sample will be 
taken at rest and every minute throughout the duration of the exercise test. During the 
exercise, a nose clip will be attached to my nose and a rubber mouthpiece attached to a 
headset, which then will be placed in my mouth. This will remain in position for the duration of 
the test. During the test, I will be closely monitored with an electrocardiogram (ECG) and by 
medical personnel 
Study day 3:
The morning of study day 3 (a minimum of 48hrs after study day 2), I will have a repeated 
breathing test. I will then wear the ventilator for two hours, throughout which I will have my 
blood pressure monitored. Before wearing the ventilator, a cannula/ line will be inserted into a 
vein in my forearm and blood samples taken before and after the ventilator. Immediately after 
this, I will undergo my second exercise stress test which will be under the same conditions as 
my previous exercise test in the laboratory.
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Benefits:
I will receive a copy of my personal spirometry and exercise fitness test after the study as well
as a summary of the overall results. There are no other direct benefits to me.
Discomforts and Risks:
1. Exercise testing carries with it a very small risk of abnormal heart rhythms, heart attack, or 
death in less than one in 30,000 patients. As I will be asked to give a maximum effort, I 
may experience some muscle soreness in my arms and legs following each maximal 
exercise test.
2. Drawing blood causes pain where the needle is inserted and can leave a bruise. A person 
trained to take blood will be used to decrease these risks.
3. The amount of blood drawn is not harmful, however, if I have a history of anemia, I should 
inform the investigator.
4. There is a small possibility of eye irritation if there is a leak from the full face mask, and of a 
blocked nose sensation. Blood pressure may fall initially when put on the ventilator.
5. Spirometry can cause light-headedness and dizzyness
Exclusion from participation:
You cannot be in this study if any of the following are true:
•  Not diagnosed with Chronic Obstructive Pulmonary Disease.
•  Not within the age requirements: 40-75yrs.
•  No recent exacerbations within one month
Alternative treatments:
You do not have to be a part of this study to be treated. There are other medications available
that can be used to treat your complaint and your doctor has discussed this with you
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Confidentiality :
All records associated with my participation in this study will be subject to usual confidentiality 
standards applicable to medical records, and in the event of any publication resulting from the 
research no personally identifiable information will be disclosed.
Compensation:
The Doctors are covered by standard medical malpractice insurance. Nothing in this document 
restricts or curtails your rights.
Voluntary Participation:
You have volunteered to participate in this study. You may quit at any time. If you decide not 
to participate, or if you quit, you will not be penalised and will not give up any benefits, which 
you had before entering the study.
Stopping the study:
I understand that my participation in this research may be terminated by the investigator 
without regard to my consent if I am unable or unwilling to comply with the guidelines and 
procedures explained to me.
Permission: granted 19th February 2002.
Further information:
You can get more information or answers to your questions about the study, your participation 
in the study, and your rights, from Ms Anita Doggett who can be telephoned at 4162794. If Dr 
Finbarr O’Connell learns of important new information that might affect your desire to remain 
in the study, he will tell you.
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This is to certify that I consent to and give permission for my participation as a volunteer in this 
program of investigation. I understand that I will receive a signed copy of this consent form. I 
have read this form and understand the content o f this consent form.
Volunteer’s Signature Date
I, the undersigned, have defined and explained the studies involved to the above volunteer.
Investigator’s Signature Date
Witness’s Signature Date
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